Search the Newsreel

CNTX Hits Worst Day In History After Ovarian Cancer Trial Data — But Analysts See Buying Opportunity In Dip

Context Therapeutics (CNTX) shares plunged 51% after reporting modest early-stage trial data for its experimental cancer drug CTIM-76 in ovarian cancer patients. Despite the stock's worst day ever, analysts from H.C. Wainwright and JonesResearch maintain "Buy" ratings, viewing the selloff as a buying opportunity …

Context Therapeutics Inc (CNTX) Stock News Today

Context Therapeutics Inc (CNTX) Earnings Forecast: Future EPS & Revenue Growth Estimates

Context Therapeutics Inc. Stock 12‑Month Price Target Cut to $4.56, Implies 557% Upside

Analysts have lowered their average 12-month price target for Context Therapeutics Inc. (CNTX) stock from $5.44 to $4.56, with forecasts ranging from $2 to $6 per share. This new target still implies a significant upside of approximately 557% based on the August 5th closing …

Context Therapeutics Inc. 1H 2026: Net income $(23.24)M, Diluted EPS $(0.24) — 10-Q Summary

Context Therapeutics Inc. reported a consolidated net loss of $(23.24)M for the first half of 2026, an increase from $(13.40)M in the prior year, with diluted loss per share rising to $(0.24) from $(0.14). The company has reprioritized its pipeline to focus on CTIM-76 …

Context Therapeutics Stock (CNTX) is Falling After Hours: Here's What's Driving the Move

Context Therapeutics (CNTX) stock fell over 30% in after-hours trading following the announcement of its second-quarter financial results, which reported a net loss of $14.6 million, up from $8.8 million in the prior year. The company is discontinuing development of CT-95 to prioritize its …

Context Therapeutics (NASDAQ:CNTX) Announces Earnings Results, Misses Expectations By $0.05 EPS

Context Therapeutics (NASDAQ:CNTX) reported a Q2 loss of $0.15 per share, missing the analyst consensus estimate by $0.05. Despite the miss, the stock rose $0.07 to $0.69, though it remains near its 1-year low and significantly below its 1-year high. Analysts currently give CNTX …

Context Therapeutics Ends CT-95, Focuses on Two Cancer Programs

Context Therapeutics (Nasdaq: CNTX) announced its Q2 2026 financial results, revealing a strategic shift to prioritize its CTIM-76 and CT-202 T cell engager programs while discontinuing the CT-95 program. The company reported $43.0 million in cash and cash equivalents, projected to fund operations into …

Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress

Context Therapeutics Inc. announced its financial results for Q2 2026, highlighting the prioritization of its CTIM-76 and CT-202 clinical programs. The company reported $43.0 million in cash and cash equivalents, expected to fund operations into Q4 2027, and anticipates initial clinical readouts for its …

Context Therapeutics (NASDAQ: CNTX) reports $23.2 million loss and cash runway

Context Therapeutics (NASDAQ: CNTX) reported a net loss of $23.2 million for the six months ended June 30, 2026, primarily due to increased research and development spending, including a $6.5 million payment for the BioAtla license amendment. The clinical-stage biopharmaceutical company is focusing its …

Context Therapeutics (CNTX) Earnings Date and Reports 2026

Context Therapeutics Receives Nasdaq Minimum Bid Price Notice

Context Therapeutics (CNTX) has received a notice from Nasdaq stating that its common stock is no longer in compliance with the Minimum Bid Price Rule, as it closed below $1.00 per share for 30 consecutive business days. The company has 180 days to regain …

Context Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard

Context Therapeutics (CNTX) received a notice from Nasdaq on July 29, 2026, indicating non-compliance with the $1.00 minimum bid price rule for 30 consecutive business days. The company has until January 25, 2027, to regain compliance by maintaining a $1.00 closing bid for at …

Context Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview

Context Therapeutics Inc is expected to report a loss of 9 cents per share, according to an earnings preview. This information is provided through TradingView News, sourced from Refinitiv.

Context Therapeutics (NASDAQ: CNTX) faces Nasdaq minimum bid-price deficiency risk

Context Therapeutics Inc. (NASDAQ: CNTX) has received a notice from Nasdaq for non-compliance with the minimum bid price rule, as its stock traded below $1.00 for 30 consecutive business days. The company has an initial 180-day grace period, until January 25, 2027, to regain …

Context Therapeutics (CNTX): Octagon group reports 3.3% beneficial stake in Schedule 13G/A

Octagon Capital Advisors LP, Octagon Investments Master Fund LP, and Ting Jia have jointly reported a 3.3% beneficial ownership in Context Therapeutics Inc. (CNTX) through a Schedule 13G/A filing. This group beneficially owns 3,050,000 shares of common stock, representing 3.3% of the outstanding shares …

Context Therapeutics Inc. (NASDAQ:CNTX) Receives Average Rating of "Moderate Buy" from Analysts

Context Therapeutics Inc. (NASDAQ:CNTX) has received an average "Moderate Buy" rating from analysts, with a consensus 12-month price target of $6.17. Despite this, the stock recently opened at $0.60, near its one-year low and significantly below its moving averages. Institutional investors hold 14.03% of …

CNTX|Context Therapeutics Inc|Price:0.591|Chg%:-0.032

This article provides a detailed financial overview of Context Therapeutics Inc (CNTX), including real-time quotes, market trends, key figures, and analyst ratings. It highlights that the company is a clinical-stage biopharmaceutical firm focusing on T cell engaging bispecific antibodies for solid tumors, with a …

Context Therapeutics, Inc. Revenue Breakdown – FWB:6K9

This page on TradingView provides a financial overview of Context Therapeutics, Inc. (FWB:6K9), focusing on its revenue breakdown. It lists various sections related to the company's financials, including statements, statistics, dividends, earnings, and segment performance. The content indicates that the financial data is sourced …

BlackRock (NYSE: BLK) discloses 6.7% ownership of Context Therapeutics (CNTX)

BlackRock, Inc. has disclosed a beneficial ownership of 6.7% in Context Therapeutics Inc. (CNTX) as of June 30, 2026, through a Schedule 13G SEC filing. This stake comprises 6,169,250 shares of common stock, with BlackRock holding sole voting power over 6,087,367 shares and sole …

Context Therapeutics Inc (CNTX) Income Statement

This article provides the quarterly and annual income statements for Context Therapeutics Inc (CNTX), detailing various financial metrics such as operating expenses, R&D expenses, operating profit, and net income. It covers financial data from FY2020Q1 through FY2026Q1, offering insights into the company's financial performance …

Octagon Capital Advisors LP Takes $13.76 Million Position in Context Therapeutics Inc. $CNTX

Context Therapeutics Inc (CNTX) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Context Therapeutics Inc (CNTX), listing its major shareholders and their respective proportions. It also presents institutional shareholding data across various quarters, including the number of institutions, shares held, and changes in proportion. Key institutional investors and their …

Context Therapeutics Inc (CNTX) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Context Therapeutics Inc (CNTX) stock, including its current trading price and market capitalization. It specifically notes that no dividend data is available for CNTX, indicating that the company has not distributed dividends in the past five years. The …

Context Therapeutics Inc (CNTX) Cash Flow

This article provides a detailed cash flow statement for Context Therapeutics Inc (CNTX), covering quarterly and annual data for operating, investing, and financing activities. It presents financial figures related to net income, capital expenditures, and changes in working capital, along with explanations of key …

Context Therapeutics Inc (CNTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey attempts to provide a revenue breakdown for Context Therapeutics Inc (CNTX) by business segments and regions. However, the company has not yet disclosed the relevant financial data. Therefore, the article primarily states the unavailability of this specific revenue information.

Context Therapeutics Inc (CNTX) Institutional Confidence

This article from TradingKey provides an overview of the institutional confidence in Context Therapeutics Inc (CNTX). It lists key institutional shareholders, their share holdings, and recent changes in their positions. The data highlights significant institutional investment in the company.

Context Therapeutics Inc (CNTX) Valuation: PE, PB & Fair Value Analysis

This article from TradingKey provides a valuation overview for Context Therapeutics Inc (CNTX). It notes that relevant data for P/E, P/B, and P/CF ratios have not been disclosed by the company yet. The article lists the current stock price, market cap, and offers an …

Context Therapeutics Inc (CNTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Context Therapeutics Inc (CNTX), focusing on various indicators and moving averages. It offers insights into the stock's current status, with a breakdown of buy, sell, and neutral signals from indicators like MACD, RSI, and moving averages. The …

Context Therapeutics Inc. Revenue Breakdown – BOATS:CNTX

This article provides a brief overview of Context Therapeutics Inc. (CNTX) financial information, specifically focusing on its revenue breakdown. It highlights that no trade data is available as the market is closed, and points to various financial data points like statements, statistics, dividends, earnings, …

Context Therapeutics Inc. (CNTX) Slips 2.7% as Shares Approach Key Support - Gamma Squeeze

Context Therapeutics Inc. (CNTX) Q1 2026 Earnings: Narrowing Loss Beats Street Estimates, Stock Holds Steady

Context Therapeutics Inc. (CNTX) Q1 2026 Earnings: Narrowing Loss Beats Street Estimates, Stock Holds Steady - Dividend Growth Analysis